Skip to main content
Erschienen in: BMC Pulmonary Medicine 1/2021

Open Access 01.12.2021 | COVID-19 | Correction

Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

verfasst von: Benoît Misset, Eric Hoste, Anne Françoise Donneau, David Grimaldi, Geert Meyfroidt, Michel Moutschen, Veerle Compernolle, André Gothot, Daniel Desmecht, Mutien Garigliany, Tome Najdovski, Pierre François Laterre

Erschienen in: BMC Pulmonary Medicine | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s12890-020-01361-x.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Correction to: BMC Pulm Med (2020) 20:317 https://​doi.​org/​10.​1186/​s12890-020-01361-x

Following publication of the original article [1], it was brought to the authors’ attention that sentences in the method section were not appropriate, due to an omission in the update of a prior version.
Namely, the following sentences have been deleted in the corrected version:
“Specifically, the interim assessment of the SOC group will be based on the numbers of patients and of deaths shown in Table 2. The recommendation will be made to stop accruing patients in the SOC group if the number of deaths observed in this group suggests a true mortality rate in excess of 0.4. The rule for DSMB recommendation shown in Table 2 will not be binding.”
Table 2 has been removed, and table 3 has been re-named as “Table 2” in the corrected body text. The error has since been corrected in the original article.
Similarly, in the electronic supplement,
  • the following sentences have been deleted:
“Specifically, the interim assessment of the SOC group will be based on the numbers of patients and of deaths shown in Table 1. The recommendation will be made to stop accruing patients in the SOC group if the number of deaths observed in this group suggests a true mortality rate in excess of 0.4. The rule for DSMB recommendation shown in Table 1 will not be binding.”
  • Table 1 has been removed, and Table 2 has been re-named as “Table 1” in the corrected body text.
  • the word “three” has been replaced by “two” in the following sentence, (paragraph 9.10):
“Because of the considerable uncertainties about the outcomes that will be observed in the two arms of the trial, the DSMB will be allowed to recommend design changes based on the observed data at the times of the interim analyses.”
The authors apologize for any inconvenience caused.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
verfasst von
Benoît Misset
Eric Hoste
Anne Françoise Donneau
David Grimaldi
Geert Meyfroidt
Michel Moutschen
Veerle Compernolle
André Gothot
Daniel Desmecht
Mutien Garigliany
Tome Najdovski
Pierre François Laterre
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Schlagwort
COVID-19
Erschienen in
BMC Pulmonary Medicine / Ausgabe 1/2021
Elektronische ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01574-8

Weitere Artikel der Ausgabe 1/2021

BMC Pulmonary Medicine 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.